OncoMatch/Clinical Trials/NCT06807593
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
Is NCT06807593 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Ustekinumab for cancer.
Treatment: Ustekinumab — The goal of this clinical research study is to learn if ustekinumab can help to control immune-related diarrhea and/or colitis in cancer patients.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: checkpoint inhibitor
Patients who receive any type of ICI therapy
Cannot have received: biologic treatment for IMDC (infliximab, vedolizumab)
Exception: if these drugs were used in a previous IMDC event that occurred ≥ 1 year earlier at which time there was complete resolution of the disease
Patients have already received other biologic treatment for IMDC such as infliximab, vedolizumab, EXCEPT if these drugs were used in a previous IMDC event that occurred ≥ 1 year earlier at which time there was complete resolution of the disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify